Evaluation of Cisplatin and Cyclosporin A in Recurrent Platinum-Resistant Ovarian Cancer: A Phase II Study of the Gynecologic Oncology Group

By Manetta A.   Blessing J.A.   Hurteau J.A.  

Gynecologic Oncology, Vol. 68, Iss. 1, 1998-01 ,pp. : 45-46

Elsevier

Access to resources Recommend Favorite

Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian cancer

By Morgan Robert   Synold Timothy   Gandara David   Muggia Franco   Scudder Sidney   Reed Eddie   Margolin Kim   Raschko James   Leong Lucille   Shibata Stephen   Tetef Merry   Vasilev Steven   McGonigle Kathryn   Longmate Jeff   Yen Yun   Chow Warren   Somlo George   Carroll Mary   Doroshow James  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 4, 2004-10 ,pp. : 283-289

Springer Publishing Company

Access to resources Recommend Favorite

Paclitaxel in Recurrent Ovarian Cancer: Better Upfront? Comments On: A Phase II Study of Paclitaxel in Platinum Pretreated Ovarian Cancer. A Hellenic Cooperative Oncology Group Study

By Bulusu V.R.  

European Journal of Cancer, Vol. 33, Iss. 11, 1997-10 ,pp. : 1905-1906

Elsevier

Access to resources Recommend Favorite

Phase II Trial of Pyrazoloacridine in Recurrent Platinum-Sensitive Ovarian Cancer: A Gynecologic Oncology Group Study

By Plaxe S.C.   Blessing J.A.   Bookman M.A.   Creasman W.T.  

Gynecologic Oncology, Vol. 84, Iss. 1, 2002-01 ,pp. : 32-35

Elsevier

Access to resources Recommend Favorite

Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer

By Garcia Agustin  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 45-46

Informa Healthcare

Access to resources Recommend Favorite